BUZZ-Assertio Holdings rises after $166 million buyout by Zydus

Assertio Holdings

Assertio Holdings

ASRT

0.00

** Shares of drugmaker Assertio Holdings ASRT.O rise 3.7% to $23.38 premarket

** ASRT says Indian drugmaker Zydus Lifesciences ZYDU.NS will acquire the company for $23.50 per share or $166.4 million

** The offer from Zydus Lifesciences' subsidiary Zydus Worldwide DMCC, tops Assertio's earlier merger agreement with Garda Therapeutics, ASRT says

** Through the deal, Zydus will gain 8 FDA approved drugs for various conditions

** Zydus' offer represents a 4% premium to ASRT's last close

** The offer represents a 30.6% premium to Garda's original $18-per-share cash offer announced in April, and a 7.8% premium to Garda's revised $21.80-per-share offer announced on May 4, Assertio said

** Assertio says the deal is expected to close in the second quarter of 2026

** As of last close, ASRT was up 148% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.